![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
GAAD Medical Research Institute Inc. |
Information provided by: | GAAD Medical Research Institute Inc. |
ClinicalTrials.gov Identifier: | NCT00573573 |
A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.
Condition | Intervention | Phase |
Hyperparathyroidism |
Radiation: Far Infrared Radiation |
Phase I |
Drug Information available for: | Parathyroid |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism. |
Estimated Enrollment: | 2 |
Study Start Date: | January 2007 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1 |
Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
|
Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.
We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Ontario | |||||
The Centre for Incurable Diseases | |||||
Toronto, Ontario, Canada, M4V 1L5 |
GAAD Medical Research Institute Inc. |
Study Director: | Francis Sam, M.D. | GAAD Medical Research Institute Inc. |
Study Chair: | Kwasi Donyina, Ph.D. | GAAD Medical Research Institute Inc. |
Responsible Party: | GAAD Medical Research Institute Inc. ( Dr. Kwasi Donyina/Founder and President ) |
Study ID Numbers: | GAAD-HT-CTP1 |
First Received: | December 12, 2007 |
Last Updated: | August 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00573573 |
Health Authority: | Canada: Health Canada |
|
|
|
![]() |